Novo Nordisk A/S vs Sea Limited — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Sea Limited trades at $106.26 (market cap $64.73B). The key difference: Novo Nordisk A/S is far larger — about 3.4× Sea Limited's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Sea Limited pays none. Which is the better fit depends on your goals.
| NVO | SE | |
|---|---|---|
Market Cap | $220.53B | $64.73B |
Sector | Health | Media |
52-Week High | $71.70 | $196.50 |
52-Week Low | $35.29 | $78.16 |
Enterprise Value | $239.49B | $57.78B |
Dividend Yield | 3.63% | — |
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →